ClassID:

21595

A61K51/1093 - CPC Classification

Classification description:

Preparations containing radioactive substances for use in therapy or testing characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus; Organic compounds; Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins; Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies

Sub-classes:
Recent Application in this class:
#1
20260151521
2026-06-04

RADIOLABELED ANTI-PD-L1 ANTIBODIES FOR IMMUNO-PET IMAGING

#2
20260139066
2026-05-21

ANTI-UROKINASE PLASMINOGEN ACTIVATOR RECEPTOR IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS

#3
20260131035
2026-05-14

Mouse Anti-Human Monoclonal Antibody Against Glypican-3

#4
20260097140
2026-04-09

Radiolabelled Compounds

#5
20260053938
2026-02-26

DIELS-ALDER CONJUGATION METHODS

#6
20260048159
2026-02-19

THERAPEUTIC AGENTS AND USES THEREOF

#7
20260028406
2026-01-29

NANOBODY BASED IMAGING AND TARGETING OF ECM IN DISEASE AND DEVELOPMENT

#8
20260027222
2026-01-29

PEPTIDE LINKERS FOR CONSTRUCTION AND REDUCING AGGREGATION OF FUSION POLYPEPTIDES COMPRISING SUCH

#9
20260022179
2026-01-22

ANTIBODY MONO-OR MULTI-SPECIFIC TO EPHRIN TYPE-A RECEPTOR 10, CHIMERIC ANTIGEN RECEPTOR T-CELL EXPRESSING THE SAME AND USES THEREOF

#10
20260021213
2026-01-22

METHOD FOR PRODUCING FC-CONTAINING MOLECULE MODIFYING REAGENT

#11
20260021192
2026-01-22

PROTEINS HAVING A COVALENT WARHEAD

#12
20260000795
2026-01-01

HER3 NANOBODIES

#13
20250340662
2025-11-06

BINDING PROTEIN

#14
20250340637
2025-11-06

CD3 TARGETING ANTIBODIES AND USES THEREOF

#15
20250339571
2025-11-06

RADIOIMMUNOCONJUGATES TARGETING PHOSPHATIDYLSERINE FOR USE IN THE TREATMENT OF CANCER

#16
20250339570
2025-11-06

RADIOIMMUNOCONJUGATES AND THERAPEUTIC USES THEREOF

#17
20250333531
2025-10-30

HUMANIZED HH1

#18
20250325718
2025-10-23

IMMUNOCONJUGATES COMPRISING KALLIKREIN RELATED PEPTIDASE 2 ANTIGEN BINDING DOMAINS AND THEIR USES

#19
20250312500
2025-10-09

RADIOPHARMACEUTICALS WITH HIGH STABILITY AND RADIOLABELING EFFICIENCY AND THERANOSTIC KIT COMPRISING SAID RADIOPHARMACEUTICALS

#20
20250302977
2025-10-02

ANTIBODY-DRUG CONJUGATES COMPRISING HUMANIZED ANTIBODIES TARGETING UROKINASE TYPE PLASMINOGEN ACTIVATOR RECEPTOR ASSOCIATED PROTEIN (UPARAP)

#21
20250289875
2025-09-18

GRP78 NANOBODIES

#22
20250255994
2025-08-14

DIMERIC IMMUNOCONJUGATES FOR USE IN TREATING CANCERS AND METHODS OF USE

#23
20250235567
2025-07-24

AGENTS FOR TREATMENT OF ENDOMETRIOSIS AND OTHER BENIGN GYNECOLOGICAL NEOPLASMS

#24
20250213736
2025-07-03

SCISSION-ENHANCED NUCLEAR IMAGING AND TREATMENT

#25
20250205374
2025-06-26

METHOD FOR PROVIDING A LABELED SINGLE ISOMERIC CHEMICAL ENTITY TARGETING VECTOR BASED ON THE USE OF AN ISOMER-FREE DIENOPHILE

#26
20250145646
2025-05-08

MACROCYCLIC COMPOUNDS AND DIAGNOSTIC USES THEREOF

#27
20250135049
2025-05-01

Methods for Biological Material Labeling and Medical Imaging

#28
20250129153
2025-04-24

CELL-SURFACE ANTIBODY TO A SPECIFIC BIOMARKER OF PANCREATIC BETA-CELLS

#29
20250122280
2025-04-17

ANTI-Ly6E ANTIBODIES, IMMUNOCONJUGATES, AND USES THEREOF

#30
20250121105
2025-04-17

METHODS FOR TREATING CANCER USING COMBINATIONS OF PARP INHIBITORS AND ANTIBODY RADIOCONJUGATES

#31
20250121104
2025-04-17

EGFR-CMET-TARGETED COMPOUNDS AND USES THEREOF

#32
20250101090
2025-03-27

ANTIBODY-PEPTIDE FUSION PROTEINS FOR TREATING AMYLOID DISORDERS

#33
20250082796
2025-03-13

LABELED PROBE AND METHODS OF USE

#34
20250059281
2025-02-20

HIGH AFFINITY B7-H6 ANTIBODIES AND ANTIBODY FRAGMENTS

#35
20250009917
2025-01-09

MACROCYCLE CONTAINING COMPOUNDS AND RADIOLABELLED COMPLEXES THEREOF, AS LIGANDS IN TARGETED RADIOTHERAPY APPLICATIONS

#36
20250009908
2025-01-09

Fluorescently Labeled Immunoglobulin Single Variable Domains

#37
20250009897
2025-01-09

PHARMACEUTICAL COMPOSITION CONTAINING TAGGED SITE-ANTIHUMAN ANTIBODY FAB FRAGMENT COMPLEX

#38
20240350682
2024-10-24

STEAP2-TARGETED COMPOUNDS AND USE THEREOF

#39
20240335572
2024-10-10

RADIOLABELED ANTI-PD-L1 ANTIBODIES FOR IMMUNO-PET IMAGING

#40
20240325575
2024-10-03

LABELING OF ANTIBODIES

#41
20240261427
2024-08-08

LINKERS, DRUG LINKERS AND CONJUGATES THEREOF AND METHODS OF USING THE SAME

#42
20240254092
2024-08-01

BIFUNCTIONAL CHELATORS AND CONJUGATES

#43
20240254085
2024-08-01

CHELATORS FOR RADIOMETALS AND METHODS OF MAKING AND USING SAME

#44
20240216554
2024-07-04

RADIOIMMUNOCONJUGATES DIRECTED TO NKG2D LIGANDS FOR THE TREATMENT OF CANCER

#45
20240207412
2024-06-27

DIELS-ALDER CONJUGATION METHODS

#46
20240181095
2024-06-06

A DELTA-OPIOID RECEPTOR TARGETED AGENT FOR MOLECULAR IMAGING AND IMMUNOTHERAPY OF CANCER

#47
20240166762
2024-05-23

METHODS AND COMPOSITIONS RELATED TO ANTIBODY FRAGMENTS THAT BIND TO TUMOR-ASSOCIATED GLYCOPROTEIN 72 (TAG-72)

#48
20240108745
2024-04-04

BIOACTIVE SUBSTANCE CONJUGATE, PREPARATION METHOD THEREFOR AND USE THEREOF

#49
20240082438
2024-03-14

Bifunctional chelators and conjugates

#50
20240075172
2024-03-07

GALLIUM 68 LABELED AFFIBODY PROTEIN PET IMAGING AGENT AND USE THEREOF

#51
20230416347
2023-12-28

Antibody-peptide fusion proteins for treating amyloid disorders

#52
20230391851
2023-12-07

ANTIBODIES

#53
20230374150
2023-11-23

ANTI-PSMA ANTIBODIES AND USES THEREOF

#54
20230365707
2023-11-16

NUCLEIC ACIDS ENCODING HUMAN ANTIBODIES TO SIALYL-LEWIS A

#55
20230348605
2023-11-02

NANOBODY BASED IMAGING AND TARGETING OF ECM IN DISEASE AND DEVELOPMENT

#56
20230340111
2023-10-26

ANTIBODY FRAGMENT AGAINST FOLR1

#57
20230338590
2023-10-26

MATERIALS AND METHODS FOR TREATING CORONAVIRUS

#58
20230338589
2023-10-26

IN VIVO IMMUNOIMAGING OF INTERFERON-GAMMA

#59
20230302168
2023-09-28

DR5 RADIOIMMUNOTHERAPY IN THE TREATMENT OF SOLID CANCERS

#60
20230270895
2023-08-31

RADIOIMMUNOCONJUGATES AND CHECKPOINT INHIBITOR COMBINATION THERAPY

#61
20230270857
2023-08-31

COMPOSITIONS INCLUDING EX VIVO ARMED T CELLS WITH MULTI-SPECIFIC ANTIBODIES AND USES THEREOF

#62
20230241256
2023-08-03

NON-INTUITIVE COMBINATION OF DRUG DELIVERY CARRIERS OF THE SAME DRUG FOR SYNERGISTIC GROWTH DELAY OF SOLID TUMORS

#63
20230192853
2023-06-22

CD8 BINDING AGENTS AND USES THEREOF

#64
20230183354
2023-06-15

ANTI-CD103 ANTIBODIES

#65
20230181772
2023-06-15

ENGINEERED ANTI-PROSTATE STEM CELL ANTIGEN FUSION PROTEINS AND USES THEREOF

#66
20230133775
2023-05-04

IMMUNOTHERANOSTIC AGENT TARGETING MESENCHYMAL STEM CELL-DERIVED CANCER CELLS AND MESENCHYMAL STEM CELL ASSOCIATED DISEASE

#67
20230121556
2023-04-20

COMPOUNDS FOR FAST AND EFFICIENT CLICK RELEASE

#68
20230110178
2023-04-13

Macrocyclic Chelators and Methods of Use Thereof

#69
20230052140
2023-02-16

IGF-1R MONOCLONAL ANTIBODIES AND USES THEREOF

#70
20230037294
2023-02-09

NANOPARTICLE IMMUNOCONJUGATES

#71
20220409751
2022-12-29

Urokinase Plasminogen Activator Receptor-Targeted Radiopharmaceutical

#72
20220409737
2022-12-29

BIOCOMPATIBLE POLYMERIC DRUG CARRIERS FOR DELIVERING ACTIVE AGENTS

#73
20220378918
2022-12-01

Diels-alder conjugation methods

#74
20220323620
2022-10-13

RADIOLABELLED ANTIBODY FRAGMENTS FOR USE IN TREATING CANCER

#75
20220296737
2022-09-22

IMMUNOPET AND IMMUNOSPECT IMAGING TO IDENTIFY CYTOTOXIC T CELL ACTIVITY

#76
20220296736
2022-09-22

ADMINISTRATION OF THERAPEUTIC AGENTS TO BRAIN AND OTHER CELLS AND TISSUE

#77
20220288246
2022-09-15

ADDITIONAL MASS TAG POLYMERS FOR MASS CYTOMETRY

#78
20220287658
2022-09-15

IN VIVO IMMUNOIMAGING OF INTERLEUKIN-12

#79
20220251196
2022-08-11

Low dose antibody-based methods for treating hematologic malignancies

#80
20220226513
2022-07-21

18F-RADIOLABELED BIOMOLECULES

#81
20220184241
2022-06-16

Radiolabeled anti-PD-L1 antibodies for immuno-PET imaging

#82
20220175977
2022-06-09

COMPOUNDS AND METHODS FOR THE DETECTION OF TRPV-6 CANCERS AND DRUG DELIVERY

#83
20220143230
2022-05-12

Bifunctional do2pa derivatives, chelates with metallic cations and use thereof

#84
20220143229
2022-05-12

RADIO-PHARMACEUTICAL COMPLEXES

#85
20220143228
2022-05-12

HER3 RADIOIMMUNOTHERAPY FOR THE TREATMENT OF SOLID CANCERS

#86
20220125961
2022-04-28

THERAPEUTIC AGENTS AND USES THEREOF

#87
20220118123
2022-04-21

COMBINATION OF AR ANTAGONISTS AND TARGETED THORIUM CONJUGATES

#88
20220088232
2022-03-24

Anti-PD-L1 diabodies and the use thereof

#89
20220088231
2022-03-24

RADIOIMMUNOCONJUGATES AND DNA DAMAGE AND REPAIR INHIBITOR COMBINATION THERAPY

#90
20220088230
2022-03-24

Actinium-225 and checkpoint inhibitor combination therapy

#91
20220088212
2022-03-24

C-terminal lysine conjugated immunoglobulins

#92
20220072167
2022-03-10

Methods for Treating Cancer Using Combinations of PARP Inhibitors and Antibody Radioconjugates

#93
20220062449
2022-03-03

Labeled probe and methods of use

#94
20220024904
2022-01-27

REAGENT FOR BIOCONJUGATION VIA IRREVERSIBLE REBRIDGING OF DISULFIDE LINKAGES

#95
20220023449
2022-01-27

PHARMACEUTICAL PREPARATION

#96
20210395281
2021-12-23

MACROCYCLIC CHELATES AND USES THEREOF

#97
20210380671
2021-12-09

COMPOSITIONS TARGETING THE SOLUBLE EXTRACELLULAR DOMAIN OF E-CADHERIN AND RELATED METHODS FOR CANCER THERAPY

#98
20210355233
2021-11-18

Pharmaceutical composition containing tagged site-antihuman antibody fab fragment complex

#99
20210347709
2021-11-11

RADIOFLUORINATED GPC3-BINDING PEPTIDES FOR PET IMAGING OF HEPATOCELLULAR CARCINOMA

#100
20210340276
2021-11-04

Complex having anti-human MUC1 antibody Fab fragment, peptide linker and/or ligand

#101
20210340258
2021-11-04

High affinity B7-H6 antibodies and antibody fragments

#102
20210338772
2021-11-04

Method of treating autoimmune inflammatory crohn's disease

#103
20210330805
2021-10-28

N-acetylgalactosamino dendron-clearing agent for dota-pretargeted radioimmunotherapy

#104
20210322583
2021-10-21

RADIO-PHARMACEUTICAL COMPLEXES

#105
20210290789
2021-09-23

RADIOIMMUNOCONJUGATES AND CHECKPOINT INHIBITOR COMBINATION THERAPY

#106
20210261674
2021-08-26

Anti-IL1RAP antibodies and their use for treating humans

#107
20210252151
2021-08-19

METHOD FOR OPTICAL OPENING OF THE BLOOD-BRAIN BARRIER

#108
20210230592
2021-07-29

Targeted Self-Assembly of Functionalized Carbon Nanotubes on Tumors

#109
20210214437
2021-07-15

SYNERGISTIC ANTI-CD47 THERAPY FOR HEMATOLOGIC CANCERS

#110
20210170058
2021-06-10

Modified antibody and radioactive metal-labelled antibody

#111
20210060190
2021-03-04

Residualizing linkers and uses thereof

#112
20210046197
2021-02-18

KIT TECHNOLOGY FOR THE PRODUCTION AND LONG-TERM STORAGE OF ZR-89-PET RADIOPHARMACEUTICALS

#113
20200405890
2020-12-31

POSITRON EMISSION TOMOGRAPHY IMAGING OF ACTIVATABLE BINDING POLYPEPTIDES AND RELATED COMPOSITIONS THEREOF

#114
20200405875
2020-12-31

CKIT antibody drug conjugates

#115
20200353105
2020-11-12

Macrocyclic chelators and methods of use thereof

#116
20200353096
2020-11-12

NANOPARTICLE IMMUNOCONJUGATES

#117
20200345872
2020-11-05

RADIOLABELED ANTI-PD-L1 ANTIBODIES FOR IMMUNO-PET IMAGING

#118
20200306339
2020-10-01

Treatment and diagnosis of inflammatory disorders and HIV

#119
20200261603
2020-08-20

Anti-human MUC1 antibody Fab fragment

#120
20200255538
2020-08-13

Methods and compositions related to antibody fragments that bind to tumor-associated glycoprotein 72 (TAG-72)

#121
20200247900
2020-08-06

NUCLEIC ACIDS ENCODING HUMAN ANTIBODIES TO SIALYL-LEWIS A

#122
20200206371
2020-07-02

In vivo immunoimaging of interferon-gamma

#123
20200197547
2020-06-25

ANTI-MESOTHELIN RADIOLABELLED SINGLE DOMAIN ANTIBODIES SUITABLE FOR THE IMAGING AND TREATMENT OF CANCERS

#124
20200171174
2020-06-04

NOVEL ANTI-HUMAN MUC1 ANTIBODY FAB FRAGMENT

#125
20200138986
2020-05-07

THERAPEUTIC AGENTS AND USES THEREOF

#126
20200129632
2020-04-30

ANTIBODY DRUG CONJUGATES

#127
20200123270
2020-04-23

Anti-human CEACAM5 antibody Fab fragment

#128
20200079858
2020-03-12

ANTIBODY CONJUGATE FOR TREATING AND DETECTING BLADDER CANCER

#129
20200040094
2020-02-06

Internalizing human monoclonal antibodies targeting prostate and other cancer cells

#130
20200038527
2020-02-06

Bifunctional do2pa derivatives, chelates with metallic cations and use thereof

#131
20200025764
2020-01-23

FOXC1 ANTIBODIES AND METHODS OF THEIR USE

#132
20200009263
2020-01-09

C-terminal lysine conjugated immunoglobulins

#133
20190352380
2019-11-21

COMPOSITIONS TARGETING THE SOLUBLE EXTRACELLULAR DOMAIN OF E-CADHERIN AND RELATED METHODS FOR CANCER THERAPY

#134
20190307906
2019-10-10

Anti-human MUC1 antibody Fab fragment

#135
20190298865
2019-10-03

RADIO-PHARMACEUTICAL COMPLEXES

#136
20190298864
2019-10-03

Compositions for therapeutics, targeted PET imaging and methods of their use

#137
20190276490
2019-09-12

Methods for the iodination of biomolecules

#138
20190263903
2019-08-29

Low dose antibody-based methods for treating hematologic malignancies

#139
20190248903
2019-08-15

Anti-CLL-1 antibodies and immunoconjugates

#140
20190225693
2019-07-25

Nanobody based imaging and targeting of ECM in disease and development

#141
20190209717
2019-07-11

Compounds and methods for the detection of TRPV-6 cancers and drug delivery

#142
20190192621
2019-06-27

Treatment and diagnosis of inflammatory disorders and HIV

#143
20190127470
2019-05-02

High affinity B7-H6 antibodies and antibody fragments

#144
20190091354
2019-03-28

Radio-pharmaceutical complexes

#145
20190091353
2019-03-28

Radiolabeled drug

#146
20190083662
2019-03-21

IGF-1R monoclonal antibodies and uses thereof

#147
20190071503
2019-03-07

Humanized Anti-HLA-DR Antibodies

#148
20190048075
2019-02-14

SYNERGISTIC ANTI-CD47 THERAPY FOR HEMATOLOGIC CANCERS

#149
20190048064
2019-02-14

ANTIBODIES

#150
20190038785
2019-02-07

Compounds, compositions and associated methods using zirconium-89 in immuno-positron emission tomography

#151
20190015530
2019-01-17

Isotope preparation method

#152
20190010247
2019-01-10

Therapeutic antibodies and uses thereof

#153
20190002544
2019-01-03

Blood-brain barrier permeable peptide compositions comprising a VAB domain of an anti-amyloid-beta camelid single-domain heavy-chain only antibody

#154
20180353628
2018-12-13

Labeled probe and methods of use

#155
20180334506
2018-11-22

Methods of detecting a solid tumor with anti-IL1RAP antibodies

#156
20180327742
2018-11-15

Targeted self-assembly of functionalized carbon nanotubes on tumors

#157
20180280551
2018-10-04

Labeling of antibodies

#158
20180273441
2018-09-27

Methods for low temperature fluorine-18 radiolabeling of biomolecules

#159
20180221507
2018-08-09

Extension sequences for diabodies

#160
20180200393
2018-07-19

Radiolabelled antibody fragments for use in treating cancer

#161
20180193475
2018-07-12

CKIT antibody drug conjugates

#162
20180179269
2018-06-28

NUCLEIC ACID AND CORRESPONDING PROTEIN NAMED 158P1D7 USEFUL IN THE TREATMENT AND DETECTION OF BLADDER AND OTHER CANCERS

#163
20180161464
2018-06-14

Radiolabeled anti-PD-L1 antibodies for immuno-PET imaging

#164
20180133350
2018-05-17

Systems and methods for determining optimum patient-specific antibody dose for tumor targeting

#165
20180133342
2018-05-17

Nanoparticle immunoconjugates

#166
20180117188
2018-05-03

Radiolabeled active targeting pharmaceutical composition and the use thereof

#167
20180104305
2018-04-19

Treatment and diagnosis of inflammatory disorders and HIV

#168
20180071413
2018-03-15

NON-INVASIVE IMAGING OF TUMOR PD-L1 EXPRESSION

#169
20180044421
2018-02-15

Anti-CLL-1 antibodies and immunoconjugates

#170
20180044420
2018-02-15

Anti-CLL-1 antibodies and immunoconjugates

#171
20180009894
2018-01-11

Anti-CLL-1 antibodies and immunoconjugates

#172
20170360956
2017-12-21

Functionalized linear ligands and complexes thereof

#173
20170340759
2017-11-30

RADIO-PHARMACEUTICAL COMPLEXES

#174
20170326261
2017-11-16

BIFUNCTIONAL do2pa DERIVATIVES, CHELATES WITH METALLIC CATIONS AND USE THEREOF

#175
20170320952
2017-11-09

Isolated nucleic acid encoding an anti-IGF-1R antibody

#176
20170319721
2017-11-09

Alpha-emitting complexes

#177
20170313786
2017-11-02

Dual Variable Domain Immunoglobulin and Uses Thereof

#178
20170298142
2017-10-19

Antibodies to GRP78

#179
20170240645
2017-08-24

Anti-PMEL17 antibodies and immunoconjugates

#180
20170240643
2017-08-24

Internalizing human monoclonal antibodies targeting prostate and other cancer cells

#181
20170218081
2017-08-03

Methods and compositions related to antibody fragments that bind to tumor-associated glycoprotein 72 (TAG-72)

#182
20170202983
2017-07-20

Actinium-225 compositions of matter and methods of their use

#183
20170198007
2017-07-13

METHODS FOR IDENTIFICATION OF SITES FOR IGG CONJUGATION

#184
20170189567
2017-07-06

Cage-like bifunctional chelators, copper-64 radiopharmaceuticals and PET imaging using the same

#185
20170128527
2017-05-11

PROLACTIN RECEPTOR ANTAGONISTS FOR TREATMENT OF GLIOBLASTOMA

#186
20170121424
2017-05-04

IMMUNO-PET IMAGING OF ANTIBODIES AND IMMUNOCONJUGATES AND USES THEREFOR

#187
20170115311
2017-04-27

Bacteriophage gene 3 protein compositions and use as amyloid binding agents

#188
20170081414
2017-03-23

Method of treating a solid tumor with IL1RAP antibodies

#189
20170066828
2017-03-09

Humanized anti-HLA-DR antibodies

#190
20170035905
2017-02-09

Antibody drug conjugates

#191
20170035903
2017-02-09

Antibodies, antibody drug conjugates and methods of use

#192
20170015756
2017-01-19

NUCLEIC ACIDS ENCODING HUMAN ANTIBODIES TO SIALYL-LEWIS A

#193
20170000911
2017-01-05

Radiotherapeutic particles and suspensions

#194
20160355575
2016-12-08

Oligopeptide and methods for producing conjugates thereof

#195
20160354499
2016-12-08

Radio-imaging and radio-therapy of cancer using antibodies to HAAH

#196
20160339077
2016-11-24

Treatment and diagnosis of inflammatory disorders and HIV

#197
20160333098
2016-11-17

Class of monospecific and bispecific humanized antibodies that target the insulin-like growth factor type I receptor (IGF-1R)

#198
20160319030
2016-11-03

Antibodies that bind OV064 and methods of use therefor

#199
20160319020
2016-11-03

Anti-CD19 antibodies

#200
20160287733
2016-10-06

Picolinate cross-bridged cyclams, chelates with metallic cations and use thereof

#201
20160279272
2016-09-29

Residualizing linkers and uses thereof

#202
20160151519
2016-06-02

Selectin ligands useful in the diagnosis and treatment of cancer

#203
20160114063
2016-04-28

PHARMACEUTICAL PREPARATION

#204
20160090423
2016-03-31

Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity

#205
20160090411
2016-03-31

NUCLEIC ACID AND CORRESPONDING PROTEIN NAMED 158P1D7 USEFUL IN THE TREATMENT AND DETECTION OF BLADDER AND OTHER CANCERS

#206
20160083461
2016-03-24

Antigen associated with the neovasculature of tumour metastases

#207
20160075787
2016-03-17

Anti-CLL-1 antibodies and immunoconjugates

#208
20160074541
2016-03-17

Prosthetic compounds for labeling internalizing biomolecules

#209
20160068593
2016-03-10

Monoclonal antibody against necrosis marker PRDX4 and use thereof

#210
20160046701
2016-02-18

COMPOSITIONS TARGETING THE SOLUBLE EXTRACELLULAR DOMAIN OF E-CADHERIN AND RELATED METHODS FOR CANCER THERAPY

#211
20160030594
2016-02-04

cKIT antibody drug conjugates

#212
20160024207
2016-01-28

Monoclonal antibodies targeting EpCAM for detection of prostate cancer lymph node metastases

#213
20160022810
2016-01-28

Method for Treating Cancers by Alternating Immunotherapeutics and Directly Oncolytic Therapeutics

#214
20160009766
2016-01-14

Bacteriophage gene 3 protein compositions and use as amyloid binding agents

#215
20160002121
2016-01-07

Methods and compositions for radiohalogen protein labeling

#216
20150374847
2015-12-31

Anti-PMEL17 antibodies and immunoconjugates

#217
20150343087
2015-12-03

Class I anti-CEA antibodies and uses thereof

#218
20150322546
2015-11-12

Method and device for producing crude copper

#219
20150315289
2015-11-05

Antibodies reactive with an epitope located in the N-terminal region of MUC5AC comprising cysteine-rich subdomain 2 (Cys2)

#220
20150297762
2015-10-22

Monoclonal antibody DS6, tumor-associated antigen CA6, and methods of use thereof

#221
20150283275
2015-10-08

Radiolabelled antibody and uses thereof

#222
20150283274
2015-10-08

Radioisotope trithiol complexes

#223
20150258223
2015-09-17

RECEPTOR BINDING CONJUGATES

#224
20150231285
2015-08-20

Radiolabeled active targeting pharmaceutical composition and the use thereof

#225
20150218273
2015-08-06

ONCOFETAL ANTIGEN/IMMATURE LAMININ RECEPTOR ANTIBODIES FOR DIAGNOSTIC AND CLINICAL APPLICATIONS

#226
20150216997
2015-08-06

Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity

#227
20150202320
2015-07-23

Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity

#228
20150202255
2015-07-23

Treatment and diagnosis of inflammatory disorders and HIV

#229
20150197577
2015-07-16

PSMA ANTIBODIES AND USES THEREOF

#230
20150196665
2015-07-16

Dosages of Immunoconjugates of Antibodies and SN-38 for Improved Efficacy and Decreased Toxicity

#231
20150196664
2015-07-16

Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity

#232
20150196662
2015-07-16

Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity

#233
20150196661
2015-07-16

Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity

#234
20150183880
2015-07-02

Methods of treating cancer with antibodies that target the insulin-like growth factor type I receptor (IGF-1R)

#235
20150182644
2015-07-02

Compounds and methods for the detection of TRPV-6 cancers and drug delivery

#236
20150165076
2015-06-18

Anti-mucin antibodies for early detection and treatment of pancreatic cancer

#237
20150111279
2015-04-23

Class I anti-CEA antibodies and uses thereof

#238
20150110817
2015-04-23

Radio-pharmaceutical complexes

#239
20150104385
2015-04-16

RADIO-PHARMACEUTICAL COMPLEXES

#240
20150098901
2015-04-09

Actinium-225 compositions of matter and methods of their use

#241
20150071853
2015-03-12

NUCLEOTIDE AND PROTEIN SEQUENCES OF AN ANTIBODY DIRECTED AGAINST AN EPITOPE COMMON TO HUMAN ACIDIC AND BASIC FERRITINS, MONOCLONAL ANTIBODIES OR ANTIBODY-LIKE MOLECULES COMPRISING THESE SEQUENCES AND USE THEREOF

#242
20150071852
2015-03-12

FOXC1 ANTIBODIES AND METHODS OF THEIR USE

#243
20150056220
2015-02-26

Methods for identification of sites for IgG conjugation

#244
20150056133
2015-02-26

CX3CR1-targeting imaging agents and their use in the diagnosis and treatment of disease

#245
20150017094
2015-01-15

ZIRCONIUM-RADIOLABELED, CYSTEINE ENGINEERED ANTIBODY CONJUGATES

#246
20150004167
2015-01-01

Dual Variable Domain Immunoglobulin and Uses Thereof

#247
20140369924
2014-12-18

SYNERGISTIC ANTI-CD47 THERAPY FOR HEMATOLOGIC CANCERS

#248
20140335016
2014-11-13

Bacteriophage gene 3 protein compositions and use as amyloid binding agents

#249
20140328753
2014-11-06

Antibodies for molecular imaging of vulnerable plaques in atherosclerosis

#250
20140328751
2014-11-06

Antibodies that bind OV064 and methods of use therefor

#251
20140322134
2014-10-30

Treating macular degeneration using antibodies to aminophospholipids

#252
20140322129
2014-10-30

Anti-B7-H4 antibodies and immunoconjugates

#253
20140316186
2014-10-23

Antibodies to TIP-1

#254
20140308203
2014-10-16

Targeted self-assembly of functionalized carbon nanotubes on tumors

#255
20140286862
2014-09-25

Therapeutic agents and uses thereof

#256
20140286859
2014-09-25

PSMA antibodies and uses thereof

#257
20140271688
2014-09-18

Antibody drug conjugates

#258
20140271685
2014-09-18

Internalizing human monoclonal antibodies targeting prostate and other cancer cells

#259
20140256916
2014-09-11

Immuno imaging agent for use with antibody-drug conjugate therapy

#260
20140227179
2014-08-14

Anti-mucin antibodies for early detection and treatment of pancreatic cancer

#261
20140227178
2014-08-14

Humanized anti-HLA-DR antibodies

#262
20140219914
2014-08-07

Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity

#263
20140170148
2014-06-19

BISPECIFIC ANTIBODIES AGAINST HER2

#264
20140170064
2014-06-19

Methods and compositions for radiohalogen protein labeling

#265
20140147384
2014-05-29

Radioimunoconjugates and uses thereof

#266
20140140924
2014-05-22

Humanized L243 antibodies

#267
20140112865
2014-04-24

Anti-CD19 antibodies

#268
20140093450
2014-04-03

Pretargeting kit for imaging or therapy comprising a trans-cyclooctene dienophile and a diene

#269
20140065065
2014-03-06

Tc imaging agents and methods of use

#270
20140051145
2014-02-20

NUCLEIC ACID AND CORRESPONDING PROTEIN NAMED 158P1D7 USEFUL IN THE TREATMENT AND DETECTION OF BLADDER AND OTHER CANCERS

#271
20140051096
2014-02-20

NUCLEIC ACID AND CORRESPONDING PROTEIN NAMED 158P1D7 USEFUL IN THE TREATMENT AND DETECTION OF BLADDER AND OTHER CANCERS

#272
20140017167
2014-01-16

Method of treatment of a solid tumor with interleukin-1 accessory protein antibody

#273
20140004038
2014-01-02

COMBINATORIAL THERAPY

#274
20130330275
2013-12-12

MISFOLDED PROTEINS IN CANCER TREATMENT AND DIAGNOSIS

#275
20130295007
2013-11-07

Anti-PMEL17 antibodies and immunoconjugates

#276
20130272959
2013-10-17

Agents for clearing biomolecules from circulation

#277
20130272958
2013-10-17

Anti-CEACAM6 antibodies and uses thereof

#278
20130195756
2013-08-01

99mTc IMAGING AGENTS AND METHODS OF USE

#279
20130189184
2013-07-25

Pretargeting kit, method and agents used therein

#280
20130183235
2013-07-18

Alpha-emitting complexes

#281
20130171064
2013-07-04

Anti-CD74 immunoconjugates and methods of use

#282
20130164216
2013-06-27

Bladder cancer tumor marker, antibody and use thereof

#283
20130143294
2013-06-06

Nucleic acid and corresponding protein named 158P1D7 useful in the treatment and detection of bladder and other cancers

#284
20130123471
2013-05-16

Antibody against carcinoembryonic antigen and uses thereof

#285
20130121913
2013-05-16

Anti-CD19 antibodies

#286
20130078182
2013-03-28

Structural Variants of Antibodies for Improved Therapeutic Characteristics

#287
20130071324
2013-03-21

Radioactive metal-labeled anti-cadherin antibody

#288
20130058864
2013-03-07

Antibodies that bind OV064 and methods of use therefor

#289
20130052667
2013-02-28

Nucleic acid and corresponding protein named 158P1D7 useful in the treatment and detection of bladder and other cancers

#290
20130040361
2013-02-14

Antigen associated with the neovasculature of tumour metastases

#291
20130040311
2013-02-14

Monoclonal antibody against necrosis marker ERP29 and use thereof

#292
20130034492
2013-02-07

Class I anti-CEA antibodies and uses thereof

#293
20130004423
2013-01-03

Polyazamacrocyclic compound, and a production method and a biomedical use therefor

#294
20130004416
2013-01-03

Dual Variable Domain Immunoglobulin and Uses Thereof

#295
20120328528
2012-12-27

Monoclonal antibody against necrosis marker PRDX4 and use thereof

#296
20120301396
2012-11-29

Radioimmunoconjugates and uses thereof

#297
20120282174
2012-11-08

Synergistic anti-CD47 therapy for hematologic cancers

#298
20120276001
2012-11-01

Bifunctional polyazamacrocyclic chelating agents

#299
20120263644
2012-10-18

Treatment and diagnosis of inflammatory disorders and HIV

#300
20120251446
2012-10-04

Peptide Conjugates Comprising Polyhistidine Sequence and Free Cysteine and Their Uses in Imaging